Advaxis Reports Updated Phase 2 Cervical Cancer Trial Data at NCI/GOG Meeting
08:30 EDT 30 Jul 2012 | Businesswire
This article has expired, however you can still
download the PDF.
Preview:
Advaxis,
Inc., (OTCBB: ADXS), a leader in
developing the next generation of immunotherapies for cancer and
infectious diseases, presented updated preliminary data from an ongoing
randomized Phase 2 trial of ADXS-HPV being...
Other Sources for this Article
Advaxis, Inc.
Diana Moore, 609-452-9814
Director, Investor
Relations & Business Development
dmoore@advaxis.com
More From BioPortfolio on "Advaxis Reports Updated Phase 2 Cervical Cancer Trial Data at NCI/GOG Meeting"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
